PJ-01

**PJ-01** is an Essemblix-engineered, prostate cancer-targeted docetaxel therapeutic developed by Parabon NanoLabs with scientific input and testing support from Janssen. The single investigational compound was designed to preferentially deliver the microtubule-stabilizing chemotherapy payload docetaxel to prostate tumor cells and includes undisclosed moieties intended to increase prostate cancer-cell responsiveness, with the objective of improving antitumor activity while reducing systemic toxicity. The targeting ligand, carrier architecture, linker chemistry, sensitizing components, dosage form, route, and clinical-stage progression have not been publicly disclosed. ([www03.parabon-nanolabs.com](https://www03.parabon-nanolabs.com/news-events/2012/12/Parabon_NanoLabs-NSF_Janssen_TECP_Award.html))